June 25, 2026 FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)
June 25, 2026 Social Media Victims Law Center Lawsuit Claims Snap’s Design Enabled Predator to Find, Groom, and Sexually Assault 12‑Year‑Old Missouri Girl
June 25, 2026 Intelivation Technologies Announces First Clinical Use of Advantage-C™ Ti3D Cervical Interbody Device
